AnaptysBio (NASDAQ:ANAB) Stock Price Down 4.5% – Here’s What Happened

AnaptysBio, Inc. (NASDAQ:ANAB) fell 4.5% during mid-day trading on Wednesday . The company traded as low as $17.29 and last traded at $17.23. 62,356 shares were traded during mid-day trading, a decline of 91% from the average session volume of 707,790 shares. The stock had previously closed at $18.04.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ANAB. UBS Group raised their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Guggenheim decreased their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Wells Fargo & Company decreased their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, Truist Financial dropped their price target on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.45.

AnaptysBio Trading Up 2.9 %

The business’s 50 day simple moving average is $17.46 and its 200 day simple moving average is $27.22. The firm has a market capitalization of $545.61 million, a PE ratio of -2.95 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. Analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Insider Activity

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were bought at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ANAB. Values First Advisors Inc. bought a new stake in shares of AnaptysBio during the 3rd quarter worth approximately $49,000. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 644 shares during the last quarter. Point72 DIFC Ltd boosted its stake in shares of AnaptysBio by 680.5% during the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 5,342 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of AnaptysBio by 35.0% in the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 4,231 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.